On June 14, 2026, Legend Biotech announced first-in-human clinical proof-of-concept data for LB2501, an investigational in vivo CD19/CD20 dual-targeting CAR-T cell therapy, for patients with relapsed or refractory B-cell non-Hodgkin lymphoma. The data was presented at the EHA 2026 conference. Legend Biotech is a biopharmaceutical company that develops and commercializes cell therapies for the treatment of cancer.
